IMMUNOVANT INC (IMVT) — insider trading
Health Care · NASDAQ
IMMUNOVANT INC (IMVT) has 40 reported SEC Form 4 insider transactions in our data, including 21 open-market sales among the most recent 40 (latest 2026-07-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 77 | $39.99 | $3.1K | Form 4 |
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 1,399 | $39.53 | $55.3K | Form 4 |
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 105 | $39.99 | $4.2K | Form 4 |
| 2026-07-08 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 1,906 | $39.53 | $75.3K | Form 4 |
| 2026-07-08 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 63 | $39.99 | $2.5K | Form 4 |
| 2026-07-08 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 1,143 | $39.53 | $45.2K | Form 4 |
| 2026-07-08 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 106 | $39.99 | $4.2K | Form 4 |
| 2026-07-08 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 1,930 | $39.53 | $76.3K | Form 4 |
| 2026-07-02 | Venker Eric | Director, Officer (Chief Executive Officer) | Open-market sale | 3,092 | $38.48 | $119.0K | Form 4 |
| 2026-07-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 92,188 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Disposition to the issuer | 86,629 | $38.14 | $3.30M | Form 4 |
| 2026-07-01 | Venker Eric | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 92,188 | $14.46 | $1.33M | Form 4 |
| 2026-06-26 | Pande Atul | Director | Option exercise / conversion (derivative) | 1,500 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Pande Atul | Director | Open-market sale | 1,500 | $38.01 | $57.0K | Form 4 |
| 2026-06-26 | Pande Atul | Director | Option exercise / conversion | 1,500 | $8.43 | $12.6K | Form 4 |
| 2026-06-26 | Girao Tiago | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 10,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Girao Tiago | Officer (Chief Financial Officer) | Open-market sale | 10,000 | $38.46 | $384.6K | Form 4 |
| 2026-06-26 | Girao Tiago | Officer (Chief Financial Officer) | Option exercise / conversion | 10,000 | $15.90 | $159.0K | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 17,824 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 2,842 | $38.96 | $110.7K | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 14,982 | $38.19 | $572.2K | Form 4 |
| 2026-06-26 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Option exercise / conversion | 17,824 | $15.20 | $270.9K | Form 4 |
| 2026-06-26 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 6,723 | $38.94 | $261.8K | Form 4 |
| 2026-06-26 | Stout Jay S | Officer (Chief Technology Officer) | Open-market sale | 33,277 | $38.18 | $1.27M | Form 4 |
| 2026-06-26 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 2,966 | $38.95 | $115.5K | Form 4 |
| 2026-06-26 | Gloria Melanie | Officer (Chief Operating Officer) | Open-market sale | 14,748 | $38.18 | $563.1K | Form 4 |
| 2026-06-18 | Van Tuyl Christopher | Officer (Chief Legal Officer) | Open-market sale | 2,634 | $35.39 | $93.2K | Form 4 |
| 2026-06-15 | Pande Atul | Director | Option exercise / conversion (derivative) | 1,500 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Pande Atul | Director | Open-market sale | 1,500 | $34.02 | $51.0K | Form 4 |
| 2026-06-15 | Pande Atul | Director | Option exercise / conversion | 1,500 | $8.43 | $12.6K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 16,260 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 77,181 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 71,492 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion (derivative) | 31,668 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Open-market sale | 210,468 | $33.56 | $7.06M | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Open-market sale | 11,483 | $32.64 | $374.8K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 16,260 | $14.70 | $239.0K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 77,181 | $8.43 | $650.6K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 71,492 | $7.94 | $567.6K | Form 4 |
| 2026-05-28 | Fromkin Andrew J. | Director | Option exercise / conversion | 31,668 | $4.99 | $158.0K | Form 4 |
Ask the chat about IMVT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: IMMUNOVANT INC (IMVT).
Last updated 2026-07-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.